Takeda Pharmaceutical (NYSE:TAK) Announces Quarterly Earnings Results, Beats Estimates By $0.37 EPS

Posted by Geri Gentry on Oct 30th, 2026

Takeda Pharmaceutical (NYSE:TAK – Get Free Report) posted its quarterly earnings data on Thursday. The company reported $0.51 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.14 by $0.37, Zacks reports. The firm had revenue of $7.53 billion for the quarter, compared to the consensus estimate of $7.34 billion. Takeda Pharmaceutical had a return on equity of 10.95% and a net margin of 3.80%.

Here are the key takeaways from Takeda Pharmaceutical’s conference call:

Takeda reported first-half core revenue of JPY 2.4 trillion, down 1% at constant exchange rates, while core operating profit rose 0.7% to JPY 710.6 billion. Full-year revenue guidance remains a low-single-digit decline, but core operating profit and EPS guidance were raised primarily due to favorable foreign exchange.
Takeda has launched ORZEYFUL in Japan and China and expects a U.S. launch in early November, while MIMRYLO launched in the U.S. in August and is receiving positive physician and patient feedback. Zasocitinib filings were accepted for priority review in the U.S. and by European regulators, supporting potential approval and launch in fiscal 2026.
The company’s transformation program is progressing, with approximately 3,000 impacted roles communicated and JPY 30 billion in annualized procurement savings implemented. Takeda remains on track for JPY 100 billion in gross savings, which management says is helping fund product launches and R&D investment.
Late-stage pipeline data were encouraging: TAK-921 produced statistically significant progression-free and overall survival benefits in heavily pretreated gastric cancer, including an overall survival hazard ratio of 0.57, while ENTYVIO’s VERDICT study showed roughly a 70% reduction in ulcerative-colitis-related complications for patients treated to stringent targets.
Zasocitinib’s ulcerative colitis study showed encouraging efficacy at the 50 mg dose, but not at 75 mg, creating uncertainty because there was no clear dose-response relationship; Takeda will wait for Crohn’s disease data expected around fiscal year-end before finalizing its phase III strategy. Plasma-derived therapies also faced near-term weakness in IVIG and albumin, with albumin forecasts reduced due to market conditions and Chinese cost-containment measures.

Takeda Pharmaceutical Trading Up 4.5%

Shares of TAK stock traded up $0.90 during mid-day trading on Friday, hitting $20.91. The company’s stock had a trading volume of 3,272,042 shares, compared to its average volume of 3,014,615. The company has a debt-to-equity ratio of 0.58, a quick ratio of 0.62 and a current ratio of 1.14. The company has a market cap of $66.99 billion, a PE ratio of 61.49 and a beta of -0.07. The company’s fifty day simple moving average is $18.79 and its 200-day simple moving average is $17.52. Takeda Pharmaceutical has a 52 week low of $13.35 and a 52 week high of $21.22.

Key Stories Impacting Takeda Pharmaceutical

Here are the key news stories impacting Takeda Pharmaceutical this week:

Positive Sentiment: Earnings and guidance beat expectations: Takeda reported quarterly adjusted EPS of approximately $0.48–$0.51, well above analyst estimates, while revenue reached about $7.53 billion versus a $7.34 billion consensus. The company also raised its annual guidance, supported by operating improvements and resilient product sales. Takeda Beats Earnings Forecasts and Hikes Outlook Despite Generic Overhang
Positive Sentiment: Pipeline launch momentum: Takeda highlighted U.S., Japanese and Chinese approvals for ORZEYFUL, the U.S. launch of MIMRYLO, and progress on zasocitinib. Management expects a trio of newer blockbuster medicines to potentially generate approximately $11 billion in peak sales, offering a path to offset future patent expirations and generic competition. Takeda Announces FY2026 First-Half Results Takeda Bets on Blockbuster Drug Trio
Neutral Sentiment: Profit growth was reported: Takeda’s first-half profit and revenue improved, but the reported figures primarily confirm the earnings release rather than introduce a new catalyst. Takeda First-Half Profit Climbs
Negative Sentiment: Cash-flow quality and valuation concerns: Despite a 17% operating margin, operating cash flow declined to $2.74 billion. Analysts also note that MIMRYLO and ORZEYFUL are ramping slowly, leaving Entyvio as a major revenue driver. The Hold view reflects concerns that current valuation and debt levels may already discount much of the earnings improvement. Takeda’s Earnings Growth Has Yet to Translate to Higher Cash Flow

Insider Activity at Takeda Pharmaceutical

In other news, CEO Julie Kim sold 89,090 shares of the firm’s stock in a transaction that occurred on Monday, August 10th. The shares were sold at an average price of $17.10, for a total value of $1,523,439.00. Following the completion of the transaction, the chief executive officer directly owned 391,489 shares in the company, valued at approximately $6,694,461.90. This trade represents a 18.54% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Giles Platford sold 31,083 shares of the business’s stock in a transaction dated Monday, August 10th. The stock was sold at an average price of $17.10, for a total value of $531,519.30. Following the transaction, the insider directly owned 315,838 shares of the company’s stock, valued at $5,400,829.80. The trade was a 8.96% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold 627,457 shares of company stock valued at $10,981,175 over the last 90 days. Corporate insiders own 0.04% of the company’s stock.

Analysts Set New Price Targets

TAK has been the topic of a number of analyst reports. Zacks Research downgraded shares of Takeda Pharmaceutical from a “strong-buy” rating to a “hold” rating in a research report on Thursday, October 1st. Wall Street Zen upgraded Takeda Pharmaceutical from a “hold” rating to a “buy” rating in a report on Saturday, July 18th. Finally, Weiss Ratings upgraded Takeda Pharmaceutical from a “hold (c-)” rating to a “hold (c)” rating in a research note on Thursday, October 8th. Two investment analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company’s stock. Based on data from MarketBeat, Takeda Pharmaceutical has a consensus rating of “Moderate Buy”.

Check Out Our Latest Analysis on TAK

About Takeda Pharmaceutical

(Get Free Report)

Takeda Pharmaceutical Company Limited is a global biopharmaceutical company headquartered in Tokyo, Japan. The company researches, develops, manufactures and commercializes medicines for patients worldwide, with a focus on areas of significant unmet medical need. Its principal therapeutic areas include gastroenterology, rare diseases, plasma-derived therapies, oncology, neuroscience and vaccines.

Takeda’s portfolio includes treatments such as Entyvio for inflammatory bowel disease, Takhzyro for hereditary angioedema, and medicines for certain blood cancers and rare conditions.